You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Sodium-glucose co-transporter-2 inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Atrial Fibrillation Trial (Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor, Rhythm control and anticoagulation)

Not yet recruiting
  • Atrial Fibrillation
  • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
  • Rhythm control and anticoagulation
  • (no location specified)
Aug 14, 2023

Obesity, Type 2 Diabetes, Sodium-glucose Co-transporter-2 Inhibitor Trial (Henagliflozin, Metformin)

Not yet recruiting
  • Obesity
  • +4 more
  • (no location specified)
Sep 27, 2023

Kidney Transplant Recipients Trial in Toronto (Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL)

Not yet recruiting
  • Kidney Transplant Recipients
  • Dapagliflozin 10 MG
  • Semaglutide, 1.0 mg/mL
  • Toronto, Ontario, Canada
    Toronto General Hospital
Jul 6, 2023

Obesity, Dapagliflozin Adverse Reaction, Weight Loss Trial (Dapagliflozin 10mg Tab)

Not yet recruiting
  • Obesity
  • +3 more
  • Dapagliflozin 10mg Tab
  • (no location specified)
Aug 14, 2023

Myocardial Ischemia Trial (Dapagliflozin 10mg Tab, Placebo)

Not yet recruiting
  • Myocardial Ischemia
  • Dapagliflozin 10mg Tab
  • Placebo
  • (no location specified)
Feb 27, 2023

Metabolic Associated Fatty Liver Disease Trial (dapagliflozin (Forxiga))

Not yet recruiting
  • Metabolic Associated Fatty Liver Disease
  • dapagliflozin (Forxiga)
  • (no location specified)
Mar 13, 2023

Healthy Volunteers Trial run by the NIDDK (Placebo, Canagliflozin)

Completed
  • Healthy Volunteers
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor Trial in Netherlands (Dapagliflozin 10 MG Oral

Not yet recruiting
  • Acute Kidney Injury
  • +2 more
  • Dapagliflozin 10 MG Oral Tablet [Farxiga]
  • Placebo
  • Amsterdam, Netherlands
  • +5 more
Oct 18, 2022

Diabetic Nephropathy Type 2 Trial (Empagliflozin 25 MG, Enalapril Maleate 20 mg)

Not yet recruiting
  • Diabetic Nephropathy Type 2
  • Empagliflozin 25 MG
  • Enalapril Maleate 20 mg
  • (no location specified)
May 9, 2022

SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac

Recruiting
  • Coronary Artery Disease
  • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
  • Shah Alam, Selangor, Malaysia
    Institute for Clinical Research, National Institutes of Health,
Nov 9, 2023

Non-alcoholic Fatty Liver Disease Trial in Kanazawa (Tofogliflozin, Glimepiride)

Completed
  • Non-alcoholic Fatty Liver Disease
  • Kanazawa, Ishikawa, Japan
    Kanazawa University Graduate School of Medical Sciences
Jun 30, 2021

Aortic Valve Stenosis Trial in Strasbourg (Myocardium biopsy)

Not yet recruiting
  • Aortic Valve Stenosis
  • Myocardium biopsy
  • Strasbourg, France
    Hôpitaux Universitaires de Strasbourg
Apr 13, 2023

Acute Heart Failure Trial in Japan (Empagliflozin 10 MG, Placebo)

Recruiting
  • Acute Heart Failure
  • Empagliflozin 10 MG
  • Placebo
  • Anjo, Aichi, Japan
  • +50 more
Jan 21, 2023

Type 2 Diabetes Trial in Seoul (TZD group, SGLT-2 group)

Completed
  • Type 2 Diabetes Mellitus
  • TZD group
  • SGLT-2 group
  • Seoul, Korea, Republic of
    Division of Endocrinology and Metabolism, Department of Internal
May 3, 2021

Type2 Diabetes Trial in Seoul (Glimepiride, Empagliflozin)

Completed
  • Type2 Diabetes Mellitus
  • Seoul, Korea, Republic of
    Yonsei University College of Medicine, Department of Internal Me
Aug 24, 2020

(NIS) on Sodium-glucose Co-transporter-2 Inhibitors Use in

Not yet recruiting
  • Diabetes Mellitus, Type 2
  • Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
  • (no location specified)
May 22, 2023

Acute Pancreatitis in Type 2 Diabetes Mellitus Treated With

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • empagliflozin
  • Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim International GmbH
Aug 19, 2022

Diabetes, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors Trial in Seoul (SGLT2 inhibitor, Glimepiride)

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • Seoul, Korea, Republic of
    Yonsei University College of Medicine
Aug 1, 2023

Heart Attack, Enlarged Heart Trial in Minneapolis (Dapagliflozin, Placebo)

Recruiting
  • Heart Attack
  • Enlarged Heart
  • Minneapolis, Minnesota
    Minneapolis Heart Institute Foundation
Aug 4, 2022

Diabetic Nephropathies Trial in Cairo (SGLT2 inhibitor, ACE inhibitor)

Unknown status
  • Diabetic Nephropathies
  • SGLT2 inhibitor
  • ACE inhibitor
  • Cairo, Egypt
    Ain Shams University Hospitals
Apr 18, 2020

Heart Failure With Reduced Ejection Fraction Trial in Chicago (SGLT2i, No SGLT2i)

Recruiting
  • Heart Failure With Reduced Ejection Fraction
  • Chicago, Illinois
    University of Chicago
Nov 11, 2022

Chronic Kidney Diseases, Bone Diseases, Metabolic Trial in Mansoura (Dapagliflozin 10mg Tab, Placebo)

Active, not recruiting
  • Chronic Kidney Diseases
  • Bone Diseases, Metabolic
  • Dapagliflozin 10mg Tab
  • Placebo
  • Mansoura, Aldakahliya, Egypt
    Urology and Nephrology center, Mansoura University
Feb 16, 2023

Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas Trial in Saint Louis (Dapagliflozin, BIOSENSE meters)

Completed
Has Results
  • Pancreas Cancer
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Dec 20, 2022

SGLT2-I Use in DFUD: a Delphi Study

Not yet recruiting
  • Diabetic Foot Ulcer
  • eDelphi method
  • (no location specified)
Aug 14, 2023

Acute Decompensated Heart Failure Trial in Chicago (SGLT2i, No SGLT2i)

Not yet recruiting
  • Acute Decompensated Heart Failure
  • Chicago, Illinois
    University of Chicago
Jun 10, 2022